Antitumor activity of thalidomide in refractory multiple myeloma.
By S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, Paul Eddlemon, N. Munshi, E. Anaissie, C. Wilson, M. Dhodapkar and 4 more. 1999
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Atul J. Butte
- Tarangini Deshpande
- Joel T. Dudley
- G. Tonon
- D. Siegel
- E. Clercq
- J. Neyts
- S. Liekens
Citations in the corpus
- SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery (2013, neutral): “comparison to de novo design[4-11].”
- Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. (2006, background): “Thalidomide has shown significant single-agent activity in relapsed refractory multiple myeloma.(9) In combination with dexamethasone, response rates increase to approximately 50% in relapsed refractory disease.”
- Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. (2006, unknown): “Peripheral neuropathy 8 (1) 15 (2) 68 (7) .”
- The evolution of thalidomide and its IMiD derivatives as anticancer agents (2004, background): “Remarkably, an initial report published in 1999 indicated that thalidomide was an effective treatment in 30–40% of patients with advanced and refractory M”
- Clinical translation of angiogenesis inhibitors (2002, unknown): “gov/cancerinfo/pdq/treatment/myeloma/healthprofessional/">multiple myeloma”
- Angiogenesis: regulators and clinical applications. (2001, background): “[142] Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B.”
- Multiple myeloma: evolving genetic events and host interactions (2002, unknown): “asp?DrugCode=1%2D11465&DrugName=THALIDOMIDE+ORAL&DrugType=1">thalidomide”